These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

234 related articles for article (PubMed ID: 32664913)

  • 1. Expert consensus on the management of adverse events and prescribing practices associated with the treatment of patients taking pirfenidone for idiopathic pulmonary fibrosis: a Delphi consensus study.
    Rahaghi FF; Safdar Z; Brown AW; de Andrade JA; Flaherty KR; Kaner RJ; King CS; Padilla ML; Noth I; Scholand MB; Shifren A; Nathan SD
    BMC Pulm Med; 2020 Jul; 20(1):191. PubMed ID: 32664913
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Pirfenidone in idiopathic pulmonary fibrosis: expert panel discussion on the management of drug-related adverse events.
    Costabel U; Bendstrup E; Cottin V; Dewint P; Egan JJ; Ferguson J; Groves R; Hellström PM; Kreuter M; Maher TM; Molina-Molina M; Nordlind K; Sarafidis A; Vancheri C
    Adv Ther; 2014 Apr; 31(4):375-91. PubMed ID: 24639005
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Pirfenidone safety and adverse event management in idiopathic pulmonary fibrosis.
    Lancaster LH; de Andrade JA; Zibrak JD; Padilla ML; Albera C; Nathan SD; Wijsenbeek MS; Stauffer JL; Kirchgaessler KU; Costabel U
    Eur Respir Rev; 2017 Dec; 26(146):. PubMed ID: 29212837
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cardiovascular Risks, Bleeding Risks, and Clinical Events from 3 Phase III Trials of Pirfenidone in Patients with Idiopathic Pulmonary Fibrosis.
    Glassberg MK; Nathan SD; Lin CY; Morgenthien EA; Stauffer JL; Chou W; Noble PW
    Adv Ther; 2019 Oct; 36(10):2910-2926. PubMed ID: 31401786
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A safety evaluation of pirfenidone for the treatment of idiopathic pulmonary fibrosis.
    Anderson A; Shifren A; Nathan SD
    Expert Opin Drug Saf; 2016 Jul; 15(7):975-82. PubMed ID: 27177012
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Evaluation of efficacy and safety of pirfenidone 200 mg tablets in patients with idiopathic pulmonary fibrosis in a real-life setting.
    Coşkun F; Çilli A; Hanta İ; Sevinç C; Ödemiş A; Ursavaş A
    Turk J Med Sci; 2021 Dec; 51(6):3082-3088. PubMed ID: 34565135
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Safety and tolerability of acetylcysteine and pirfenidone combination therapy in idiopathic pulmonary fibrosis: a randomised, double-blind, placebo-controlled, phase 2 trial.
    Behr J; Bendstrup E; Crestani B; Günther A; Olschewski H; Sköld CM; Wells A; Wuyts W; Koschel D; Kreuter M; Wallaert B; Lin CY; Beck J; Albera C
    Lancet Respir Med; 2016 Jun; 4(6):445-53. PubMed ID: 27161257
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Long-term clinical and real-world experience with pirfenidone in the treatment of idiopathic pulmonary fibrosis.
    Cottin V; Maher T
    Eur Respir Rev; 2015 Mar; 24(135):58-64. PubMed ID: 25726556
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Safety and efficacy of pirfenidone in severe Idiopathic Pulmonary Fibrosis: A real-world observational study.
    Tzouvelekis A; Ntolios P; Karampitsakos T; Tzilas V; Anevlavis S; Bouros E; Steiropoulos P; Koulouris N; Stratakos G; Froudarakis M; Bouros D
    Pulm Pharmacol Ther; 2017 Oct; 46():48-53. PubMed ID: 28843616
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The effects and safety of pirfenidone in the treatment of idiopathic pulmonary fibrosis: a meta-analysis and systematic review.
    Zang C; Zheng Y; Wang Y; Li L
    Eur J Med Res; 2021 Oct; 26(1):129. PubMed ID: 34717762
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Pirfenidone for the treatment of idiopathic pulmonary fibrosis.
    Xaubet A; Serrano-Mollar A; Ancochea J
    Expert Opin Pharmacother; 2014 Feb; 15(2):275-81. PubMed ID: 24308635
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Real world experiences: pirfenidone is well tolerated in patients with idiopathic pulmonary fibrosis.
    Chaudhuri N; Duck A; Frank R; Holme J; Leonard C
    Respir Med; 2014 Jan; 108(1):224-6. PubMed ID: 24269005
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A multicentre retrospective observational study on Polish experience of pirfenidone therapy in patients with idiopathic pulmonary fibrosis: the PolExPIR study.
    Majewski S; Białas AJ; Buchczyk M; Gomółka P; Górska K; Jagielska-Len H; Jarzemska A; Jassem E; Jastrzębski D; Kania A; Koprowski M; Krenke R; Kuś J; Lewandowska K; Martusewicz-Boros MM; Roszkowski-Śliż K; Siemińska A; Sładek K; Sobiecka M; Szewczyk K; Tomczak M; Tomkowski W; Wiatr E; Ziora D; Żołnowska B; Piotrowski WJ
    BMC Pulm Med; 2020 May; 20(1):122. PubMed ID: 32366291
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Comprehensive assessment of the long-term safety of pirfenidone in patients with idiopathic pulmonary fibrosis.
    Valeyre D; Albera C; Bradford WZ; Costabel U; King TE; Leff JA; Noble PW; Sahn SA; du Bois RM
    Respirology; 2014 Jul; 19(5):740-7. PubMed ID: 24836849
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Efficacy and adverse events of pirfenidone in treating idiopathic pulmonary fibrosis.
    Ren H; Wang K; Yang H; Gao L
    Saudi Med J; 2017 Sep; 38(9):889-894. PubMed ID: 28889145
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Managing Idiopathic Pulmonary Fibrosis: Which Drug for Which Patient?
    Hayton C; Chaudhuri N
    Drugs Aging; 2017 Sep; 34(9):647-653. PubMed ID: 28861727
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Pirfenidone: a novel agent for the treatment of idiopathic pulmonary fibrosis.
    Potts J; Yogaratnam D
    Ann Pharmacother; 2013 Mar; 47(3):361-7. PubMed ID: 23404802
    [TBL] [Abstract][Full Text] [Related]  

  • 18. IPF Care: a support program for patients with idiopathic pulmonary fibrosis treated with pirfenidone in Europe.
    Duck A; Pigram L; Errhalt P; Ahmed D; Chaudhuri N
    Adv Ther; 2015 Feb; 32(2):87-107. PubMed ID: 25691376
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Pirfenidone in patients with idiopathic pulmonary fibrosis and more advanced lung function impairment.
    Nathan SD; Costabel U; Albera C; Behr J; Wuyts WA; Kirchgaessler KU; Stauffer JL; Morgenthien E; Chou W; Limb SL; Noble PW
    Respir Med; 2019 Jul; 153():44-51. PubMed ID: 31153107
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Perils with Pirfenidone and "the tuberculosis link".
    Hande MH; Acharya KV; Shreenivasa A; Nayak K; Arun S
    Int J Mycobacteriol; 2019; 8(3):298-301. PubMed ID: 31512609
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.